Dr Reddy's and Bayer Unite to Broaden Access to Heart Failure Drug in India

Dr. Reddy's Laboratories, a prominent pharmaceutical company, announced a significant partnership with Bayer, a global enterprise in the healthcare sector, to enhance the availability of Vericiguat, a medication designed for the treatment of chronic heart failure, in India. This collaboration marks a pivotal step towards addressing the healthcare needs of millions suffering from this condition across the country.

Representative image

In a strategic move dated September 2022, Bayer introduced Vericiguat in the Indian market under the brand name Verquvo. Building on this initiative, Dr. Reddy's will now market the drug under a new brand name, Gantra, thereby broadening the spectrum of treatment options available to patients with chronic heart failure.

The agreement between Dr. Reddy's and Bayer is characterized by the grant of non-exclusive rights to Dr. Reddy's for marketing Vericiguat under the Gantra brand. This arrangement is expected to significantly expand the drug's reach within India, making it more accessible to patients in need.

Chronic heart failure is identified as a critical public health concern in India, affecting an estimated 8-10 million individuals. The introduction of Gantra is seen as a reaffirmation of Bayer's commitment to improving patient access to innovative healthcare solutions. Shweta Rai, Managing Director at Bayer Zydus Pharma, emphasized the importance of making advanced treatments available to a broader patient base.

MV Ramana, CEO of Branded Markets India and Emerging Markets at Dr. Reddy's, highlighted the partnership's role in the company's ongoing efforts to bring innovative medicines to the Indian market through strategic collaborations. He noted that Dr. Reddy's would leverage its marketing and distribution strengths to ensure wider access to this novel treatment option, extending its availability from metropolitan areas to tier-I and tier-II towns across India.

This collaboration between Dr. Reddy's and Bayer represents a significant stride towards enhancing healthcare outcomes for patients with chronic heart failure in India. By making Vericiguat available under two brand names, Verquvo and Gantra, the companies aim to meet the growing needs of patients and contribute to the overall improvement of public health in the region.